- Yahoo Finance•3 days ago
Catch The Final Round with Jen Rogers and markets correspondent Nicole Sinclair. Stocks in the green today include Stemline Therapeutics after the FDA granted Breakthrough status for its acute myeloid leukemia treatment, software maker Tableau as it appointed former Amazon exec Adam Selipsky as its new CEO, and Monsanto – shares of the seed and chemical-maker growing after Bloomberg reported Bayer and Monsanto were working on an improved takeover bid. Hillary Clinton’s presidential campaign has been dogged by accusations that wealthy Clinton Foundation donors sought favors from the State Department when Clinton was at its head.
- TheStreet.com•16 days ago
Amicus Therapeutics (FOLD) CEO John Crowley joined Thursday morning's 'Squawk Box' on CNBC to discuss the future of the company and new medications in the pipeline.
- GlobeNewswire•16 days agoUPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
CRANBURY, N.J., Aug. 10, 2016-- Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 evaluating the efficacy ...
Amicus Therapeutics, Inc. (FOLD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||6.12 x 1300|
|Ask||7.01 x 800|
|Day's Range||6.63 - 7.20|
|52wk Range||4.98 - 18.40|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.96|
|Avg Vol (3m)||2,381,096|
|Dividend & Yield||N/A (N/A)|